Mr. Scott Boyes reports

THE CANADIAN BIOCEUTICAL CORPORATION APPLIES FOR $250,000 OF EQUITY FINANCING AND INCORPORATES SUBSIDIARY

The Canadian Bioceutical Corp. has applied for TSX Venture Exchange approval to consummate a private placement of 1,923,077 common shares at a price of 13 cents per share to raise $250,000 of new equity financing.

It is anticipated that the proceeds of the financing will be used as general working capital and to further develop the ANQ business model.

The private placement is non-brokered and no finder's fees are payable in association therewith.

All securities issued pursuant to this private placement will be subject to a hold period that will extend a minimum of four months subsequent to the closing of the private placement.

Upon the closing of the above-mentioned private placement, BCC would have 35,165,957 issued and outstanding common shares, 15 million common share purchase warrants, and 3,198,000 incentive stock options.

BCC also announces today that it has incorporated a wholly owned subsidiary in anticipation of entering into the medical marijuana industry. Management is presently organizing a plan and further information is expected to be available to be released in early 2015.

We seek Safe Harbor.